Travere Therapeutics

About

Travere Therapeutics is a biopharmaceutical company with a global team dedicated to working with the rare disease community to identify, develop and deliver life-changing therapies. The Company’s development efforts are led by sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) – rare kidney disorders that often lead to end-stage kidney disease. The company is also advancing TVT-058 for the treatment of classical homocystinuria, a genetic metabolic disorder that can cause life-threatening thrombotic events. Travere Therapeutics’ early research efforts include partnering with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. The Company also delivers four FDA-approved therapies, Chenodal®, Cholbam®, Thiola® and Thiola EC®, and is committed to ensuring broad access, educational and financial support for patients. For more information, visit travere.com.

Open Jobs

Company Information

23
February 19, 2021
1-10